What You Should Know:
– Wisp, the largest U.S. telehealth company focused exclusively on women’s sexual and reproductive health, has launched its new diagnostics vertical, significantly expanding its service offerings.
– With over 1.5 million patients across all 50 states, Wisp is now providing convenient, affordable at-home testing for common sexually transmitted infections (STIs), coupled with integrated follow-up care within its existing virtual ecosystem.
Wisp Launches Nationwide At-Home STI Testing to Expand Access to Women’s Diagnostic Care
Wisp is the largest pure-play women’s telehealth provider in the United States, delivering discreet, evidence-based treatments and a first-to-market product line across sexual and reproductive health. With services spanning all 50 states, Wisp continues to establish itself as a leading, all-in-one platform for women’s health.
The new Wisp At-Home Testing & Follow-Up Care service allows patients to:
· Collect swab and urine samples from home
· Ship samples to a CLIA/CAP-accredited lab using a prepaid label
· Receive accurate results within 3–5 business days
· Access discreet, evidence-based follow-up care through Wisp’s clinical team
This launch addresses rising barriers in healthcare access, including nationwide provider shortages and stigma around STI testing. It also eliminates the previous need for third-party referrals by keeping the entire diagnostic and care process within Wisp’s system.
Initial offerings include:
· Common STI Panel: Tests for Chlamydia, Gonorrhea, and Trichomoniasis
· 3-Site Panel: Detects Chlamydia and Gonorrhea from three anatomical sites
· M-Gen Panel: Screens for Mycoplasma Genitalium (Mgen)
Future plans include additional testing options in upcoming quarters, including hormonal health diagnostics and in-home blood draw services to bolster the fertility and menopause verticals.
Survey data from Wisp shows that:
· 62% of users express interest in STI testing
· STI, STD, and Herpes-related queries are up 40% year-over-year
· STIs such as Chlamydia, Gonorrhea, and Trichomoniasis disproportionately affect women under 25
According to Wisp CEO Monica Cepak, integrating diagnostics into the platform was a natural evolution, aligning with the company’s mission to deliver 360-degree care through affordability, discretion, and convenience. All test kits are priced at the lowest market rates and include free virtual consultations for follow-up.
Dr. Jillian LoPiano, MD, MPH, FACOG, emphasized the clinical impact of discreet, reliable diagnostics, noting their potential to destigmatize sexual health and empower women to proactively manage their care. By partnering with top-tier laboratories, Wisp ensures both clinical accuracy and rapid access to treatment.
The diagnostics expansion follows Wisp’s successful rollouts in fertility, weight care, and menopause support, reinforcing its commitment to democratizing access to comprehensive women’s healthcare.
